Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Posted on Linken

<< Previous

Bullboard Posts

Next >>

Post by fasttrack5on Nov 14, 2024 11:03pm

185 Views

Post# 36314196

Posted on Linken

Behind the scenes, GCAR is working hard to finalize the Pancreatic Cancer Master Protocol trial design.

Earlier this year, we shared the exciting news that we’re collaborating with Oncolytics Biotech Inc. for the evaluation of pelareorep in our forthcoming next-generation Pancreatic Cancer Master Protocol.

To learn more about this groundbreaking #clinicaltrial, visit: https://lnkd.in/g3AbCB-A

To learn more about our collaboration with Oncolytics Biotech Inc., visit: https://lnkd.in/eH3Cwgjc

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 20, 2024